品牌 |
Leading Biology | 貨號 |
APR02485G |
產(chǎn)品分類 |
Polyclonal Antibodies | 研究領(lǐng)域 |
|
產(chǎn)品概述 |
We constantly strive to ensure we provide our customers with the best antibodies. As a result of this work we offer this antibody in purified format.
We are in the process of updating our datasheets. If you have any questions regarding this update, please feel free to contact our technical support team.
This product is a high quality RELB Antibody (Ser552).
|
||
分子量 |
62kDa
|
||
細(xì)胞定位 |
Antigen Cellular Localization:
Nucleus. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Note=Colocalizes with NEK6 in the centrosome
|
||
宿主 |
Rabbit
|
||
種屬反應(yīng)性 |
Human, Mouse, Rat
|
||
靶點 |
peptide encompassing amino acid Ser 552 of human RelB
|
||
基因ID |
|||
UniProt ID |
|||
功能 |
NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF- kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF- kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52.
|
||
總結(jié) |
NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF- kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF- kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52.
|
||
儲存條件 |
Store at +4°C short term. For long-term storage, aliquot and store at -20°C or below. Stable for 12 months at -20°C. Avoid repeated freeze-thaw cycles.
|
||
應(yīng)用 |
WB, IHC-P
|
||
稀釋方法 |
IHC-P (10 μg/ml), WB (1:500-1:1000),
|
||
圖像 |
Western blot of extracts from HUVEC, 293 and HeLa cells using RelB(Ab-573) antibody. |
||
說明書 |
|||
數(shù)量 |
|
選擇 | 品牌 | 貨號 | 產(chǎn)品名稱 | 規(guī)格 | 分類 | 研究領(lǐng)域 | 說明書 | 數(shù)量 | 目錄價 | |
1 | Leading Biology | APR05963G | EGFR Antibody (Y1092) | 100 μl | Polyclonal Antibodies |
|
¥4950.00 | 訂購 詢價 | ||
2 | Leading Biology | APR03116G | BRCA1 Antibody (aa1847-1863) | 100 μl | Polyclonal Antibodies |
|
¥4950.00 | 訂購 詢價 | ||
3 | Leading Biology | AMM05633G | Bombesin Receptor 2 (extracellular) Antibody | 50 μl | Polyclonal Antibodies |
|
¥6950.00 | 訂購 詢價 | ||
4 | Leading Biology | APR10986G | AP3B1 Antibody (aa2-14) | 50 μg | Polyclonal Antibodies |
|
¥4950.00 | 訂購 詢價 | ||
5 | Leading Biology | APR11512G | Bestrophin-1 (extracellular) Antibody | 50 μl | Polyclonal Antibodies |
|
¥6950.00 | 訂購 詢價 | ||
6 | Leading Biology | APG01407G | A3 Adenosine Receptor Antibody | 50 μl | Polyclonal Antibodies |
|
¥6950.00 | 訂購 詢價 |
微信掃描二維碼,隨時隨地與小諾親密接觸,精彩活動,勁爆優(yōu)惠,觸手可得!